Company Reports

Siemens Healthineers has established a formidable presence in imaging and radiotherapy through the acquisition of Varian. Now, it is refocusing its diagnostic operations, the weakest piece among otherwise remarkably strong businesses. While we aren't sanguine about the prospect of returning growth and profitability of diagnostics to the level of its closest peers, we view Healthineers’ overall product portfolio, market presence, growth, and margins as among the best in medical technology.

Siemens Healthineers reported 2.8% organic sales growth in its fiscal third quarter, but continued pressure in diagnostics led to a second cut to its full-year revenue outlook. A one-off US tariff refund lifted quarterly profitability and prompted a EUR 0.15 increase in full-year EPS guidance.

Siemens Healthineers reported 3.1% organic sales growth but deteriorating conditions in the diagnostics segment in its fiscal second quarter. The company slightly lowered its 2026 guidance as it sees ongoing weakness in this segment. Shares were down by midsingle digits after the earnings release.

Siemens Healthineers has established a formidable presence in imaging and radiotherapy through the acquisition of Varian. Now, it is refocusing its diagnostic operations, the weakest piece among otherwise remarkably strong businesses. While we aren't sanguine about the prospect of returning growth and profitability of diagnostics to the level of its closest peers, we view Healthineers’ overall product portfolio, market presence, growth, and margins as among the best in medical technology.

Siemens Healthineers has established a formidable presence in imaging and radiotherapy through the acquisition of Varian. Now, it is refocusing its diagnostic operations, the weakest piece among otherwise remarkably strong businesses. While we aren't sanguine about the prospect of returning growth and profitability of diagnostics to the level of its closest peers, we view Healthineers’ overall product portfolio, market presence, growth, and margins as among the best in medical technology.

Siemens Healthineers reported 3.8% organic sales growth but significant challenges in the diagnostics segment in its fiscal first quarter. It reaffirmed its 2026 outlook despite the margin pressure. The shares were down midsingle digits after the earnings release.

Siemens Healthineers held its capital markets day, during which it offered more color around long-term priorities and targets. However, the Nov. 12 announcement by Siemens of its plans to distribute 30% of its stake to shareholders weighed heavily. Healthineers' stock continues to slide.

Siemens Healthineers reported 3.7% organic sales growth during the fourth quarter. The firm's 2026 outlook implies continuing pressure from tariffs. Shares were down midsingle digits after the earnings release.

Siemens Healthineers reported 7.6% organic sales growth during the third quarter, in line with FactSet consensus. Shares are trading 2.2% higher intraday on July 30.

Siemens Healthineers has established a formidable presence in imaging and radiotherapy through the acquisition of Varian. Now, it is refocusing its diagnostic operations, the weakest piece among otherwise remarkably strong businesses. While we aren't sanguine about the prospect of returning growth and profitability of diagnostics to the level of its closest peers, we view Healthineers’ overall product portfolio, market presence, growth, and margins as among the best in medical technology.

Siemens Healthineers' results showed very strong growth in imaging and margin improvement in diagnostics. Shares are up 6% in trading on Feb. 6.

Wide-moat Siemens Healthineers reported solid fourth-quarter fiscal 2024 results with revenue reaching EUR 6.3 billion, comparable growth of 5.6%. Investors responded positively with shares rising over 8% at the market’s opening on Nov. 6. While China declined by midsingle digits, other geographies delivered strong growth. Healthineers’ fiscal 2025 outlook is robust 5%-6% revenue growth and margin expansion across all segments, which is in line with our model. We maintain our fair value estimate of EUR 61 per share and view shares as undervalued.

We're initiating coverage of Siemens Healthineers with a wide moat rating and a fair value estimate of EUR 61 per share. At current levels, the shares appear moderately undervalued.

Siemens Healthineers has established a formidable presence in imaging and radiotherapy through the acquisition of Varian. Now, it is attempting to refocus its diagnostic operations, the weakest piece among otherwise remarkably strong businesses. While we aren't sanguine about the prospect of returning growth and profitability of diagnostics to the level of its closest peers, we view Healthineers’ overall product portfolio, market presence, growth, and margins as among the best in medical technology.